Shares of Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.71 and traded as low as $1.38. Akari Therapeutics shares last traded at $1.46, with a volume of 18,126 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Akari Therapeutics in a research report on Wednesday. They set a “sell” rating on the stock.
Get Our Latest Stock Report on AKTX
Akari Therapeutics Stock Performance
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Akari Therapeutics
- What is the MACD Indicator and How to Use it in Your Trading
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- NVIDIA Insiders Sell: This Is What It Means for the MarketÂ
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
